May 23, 2024 5:00pm EDT Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
May 07, 2024 4:01pm EDT Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
Apr 30, 2024 8:05am EDT Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
Apr 04, 2024 8:05am EDT Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
Mar 12, 2024 8:05am EDT Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
Mar 05, 2024 4:01pm EST Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Feb 27, 2024 8:05am EST Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
Jan 04, 2024 8:05am EST Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma
